PMID- 19031032
OWN - NLM
STAT- MEDLINE
DCOM- 20090219
LR  - 20081125
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
IP  - 188
DP  - 2009
TI  - IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
PG  - 295-317
LID - 10.1007/978-3-540-71029-5_14 [doi]
AB  - Dendritic cells (DCs) play a crucial role in linking innate and adaptive 
      immunity, by virtue of their unique ability to take up and process antigens in 
      the peripheral blood and tissues and, upon migration to draining lymph nodes, to 
      present antigen to resting lymphocytes. Notably, these DC functions are modulated 
      by cytokines and chemokines controlling the activation and maturation of these 
      cells, thus shaping the response towards either immunity or tolerance.An ensemble 
      of recent studies have emphasized an important role of type I IFNs in the DC 
      differentiation/activation, suggesting the existence of a natural alliance 
      between these cytokines and DCs in linking innate and adaptive immunity. Herein, 
      we will review how type I IFNs can promote the ex vivo differentiation of human 
      DCs and orient DC functions towards the priming and expansion of protective 
      antitumor immune responses. We will also discuss how the knowledge on type I 
      IFN-DC interactions could be exploited for the design of more selective and 
      effective strategies of cancer immunotherapy.
FAU - Santini, Stefano Maria
AU  - Santini SM
AD  - Section of Experimental Immunotherapy, Department of Cell Biology and 
      Neurosciences, Istituto Superiore di Sanita, Viale Regina Elena, Rome, 299, 00161 
      Italy. stefano.santini@iss.it
FAU - Lapenta, Caterina
AU  - Lapenta C
FAU - Santodonato, Laura
AU  - Santodonato L
FAU - D'Agostino, Giuseppina
AU  - D'Agostino G
FAU - Belardelli, Filippo
AU  - Belardelli F
FAU - Ferrantini, Maria
AU  - Ferrantini M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Interferon-alpha)
SB  - IM
MH  - Adjuvants, Immunologic/*therapeutic use
MH  - Animals
MH  - *Cancer Vaccines
MH  - Cell Culture Techniques
MH  - Cell Differentiation
MH  - Dendritic Cells/immunology/*transplantation
MH  - Humans
MH  - Immunity, Innate
MH  - *Immunotherapy, Adoptive
MH  - Interferon-alpha/metabolism/*therapeutic use
MH  - Neoplasms/immunology/*therapy
MH  - Phenotype
RF  - 82
EDAT- 2008/11/26 09:00
MHDA- 2009/02/20 09:00
CRDT- 2008/11/26 09:00
PHST- 2008/11/26 09:00 [pubmed]
PHST- 2009/02/20 09:00 [medline]
PHST- 2008/11/26 09:00 [entrez]
AID - 10.1007/978-3-540-71029-5_14 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2009;(188):295-317. doi: 10.1007/978-3-540-71029-5_14.